Aurobindo Pharma receives US FDA nod for antibiotic drug polymyxin B
The approved product, polymyxin B injection, has an estimated market size of $ 7.6 million for the twelve months ending February 2016, according to IMS
Aurobindo Pharma Limited has received final approval from the US Food & Drug Administration (FDA) to manufacture and market polymyxin B injection (500,000 units/vial). The company expects to launch the product in Q2 FY16-17. The approved product is a generic version of Eurohealth International’s Polymyxin B injection.
Polymyxin B injection is an anti-infective used in the treatment of infections of the urinary tract, meninges, bloodstream and eye caused by susceptible strains of pseudomonas aeruginosa. The approved product has an estimated market size of $ 7.6 million for the twelve months ending February 2016, according to IMS.
Polymyxin B injection is an anti-infective used in the treatment of infections of the urinary tract, meninges, bloodstream and eye caused by susceptible strains of pseudomonas aeruginosa. The approved product has an estimated market size of $ 7.6 million for the twelve months ending February 2016, according to IMS.